Madrigal Pharmaceuticals (MDGL) Other Accumulated Expenses (2010 - 2016)

Madrigal Pharmaceuticals (MDGL) has reported Other Accumulated Expenses for 7 consecutive years, with $1.4 million the latest figure, recorded in Q2 2016.

• In Q2 2016, Other Accumulated Expenses fell 73.77% year-over-year to $1.4 million; the TTM figure through Jun 2016 stood at $1.4 million (down 73.77% YoY), while the FY2015 annual figure was $5.0 million, down 19.44% from the prior year.
• Other Accumulated Expenses eased to $1.4 million in Q2 2016 per MDGL's latest filing, from $2.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $6.2 million in Q4 2014 and bottomed at $1.4 million in Q2 2016.
• Historically, Other Accumulated Expenses has averaged $4.3 million across 5 years, with a median of $4.9 million in 2014.
• Annual changes were most pronounced in 2014 — Other Accumulated Expenses surged 67.84% — and 2016, when it tumbled 73.77%.
• Madrigal Pharmaceuticals' Other Accumulated Expenses stood at $5.1 million in 2012, then climbed by 11.53% to $5.7 million in 2013, then gained by 8.03% to $6.2 million in 2014, then retreated by 19.44% to $5.0 million in 2015, then tumbled by 70.86% to $1.4 million in 2016.
• Business Quant data shows MDGL's Other Accumulated Expenses at $1.4 million in Q2 2016, $2.8 million in Q1 2016, and $5.0 million in Q4 2015.